表紙
市場調查報告書
商品編碼
219865

狂犬病(恐水症):開發中產品分析

Rabies (Infectious Disease) - Drugs In Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 108 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

狂犬病(恐水症)是由感染的動物其唾液傳染之致死性病毒,一般經咬傷傳染。其症狀有身體部分感覺消失、肌肉功能消失、吞嚥障礙、興奮、發燒、痙攣等。致病因子有與野生生物接觸、與未接種疫苗之寵物接觸等。

本報告涵括全球狂犬病(恐水症)治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

狂犬病(恐水症) - 概要

狂犬病(恐水症) - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

狂犬病(恐水症) - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

狂犬病(恐水症)的治療藥開發企業

  • Beijing Minhai Biotechnology Co Ltd
  • Celltrion Inc
  • Curevac AG
  • Humabs BioMed SA
  • Indian Immunologicals Ltd
  • Kamada Ltd
  • Molecular Targeting Technologies Inc
  • NanoViricides Inc
  • Novavax Inc
  • PaxVax Inc
  • Sanofi Pasteur SA
  • Synermore Biologics Co Ltd
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Zydus Cadila Healthcare Ltd

藥物簡介

狂犬病(恐水症) - 暫停中的計劃

狂犬病(恐水症) - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC13030IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Drugs In Development, 2021, provides an overview of the Rabies (Infectious Disease) pipeline landscape.Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 4, 5, 12, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 6 and 1 molecules, respectively.Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Rabies - Overview
  • Rabies - Therapeutics Development
  • Rabies - Therapeutics Assessment
  • Rabies - Companies Involved in Therapeutics Development
  • Rabies - Drug Profiles
  • Rabies - Dormant Projects
  • Rabies - Discontinued Products
  • Rabies - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Rabies, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Rabies - Pipeline by AIM Vaccine Co Ltd, 2021
  • Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
  • Rabies - Pipeline by Cadila Healthcare Ltd, 2021
  • Rabies - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
  • Rabies - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2021
  • Rabies - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021
  • Rabies - Pipeline by Clover Biopharmaceuticals, 2021
  • Rabies - Pipeline by CPL Biologicals Pvt Ltd, 2021
  • Rabies - Pipeline by Curevac NV, 2021
  • Rabies - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2021
  • Rabies - Pipeline by GlaxoSmithKline Plc, 2021
  • Rabies - Pipeline by Indian Immunologicals Ltd, 2021
  • Rabies - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
  • Rabies - Pipeline by Mid-Atlantic BioTherapeutics, Inc., 2021
  • Rabies - Pipeline by Molecular Targeting Technologies Inc, 2021
  • Rabies - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2021
  • Rabies - Dormant Projects, 2021
  • Rabies - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Rabies, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021